ES2180702T3 - Tratamiento de patologias por la induccion del factor de transcripcion bef-1. - Google Patents

Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Info

Publication number
ES2180702T3
ES2180702T3 ES96303876T ES96303876T ES2180702T3 ES 2180702 T3 ES2180702 T3 ES 2180702T3 ES 96303876 T ES96303876 T ES 96303876T ES 96303876 T ES96303876 T ES 96303876T ES 2180702 T3 ES2180702 T3 ES 2180702T3
Authority
ES
Spain
Prior art keywords
bef
transcription factor
pathologies
induction
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96303876T
Other languages
English (en)
Inventor
David Thompson Berg
David Scott Calnek
Brian William Grinnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2180702T3 publication Critical patent/ES2180702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

UN METODO PARA INDUCIR EL FACTOR DE TRANSCRIPCION BEF-1 QUE CONSISTE EN ADMINISTRAR A UNA PERSONA QUE LO NECESITE UNA CANTIDAD EFICAZ DE UN COMPUESTO CON LA FORMULA DONDE R{SUP,1} Y R{SUP,3} SON, INDEPENDIENTEMENTE, HIDROGENO, CH{SUB,3}, -C=O-(C{SUB,1}-C{SUB,6} ALQUIL) O -C=O-AR, DONDE AR ES UN FENILO OPCIONALMENTE SUSTITUIDO; R{SUP,2} SE SELECCIONA DE UN GRUPO FORMADO POR PIRROLIDINA, HEXAMETILENAMINO Y PIPERIDINO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTOS COMPUESTOS SOLVATADOS.
ES96303876T 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1. Expired - Lifetime ES2180702T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47949895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2180702T3 true ES2180702T3 (es) 2003-02-16

Family

ID=23904277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96303876T Expired - Lifetime ES2180702T3 (es) 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Country Status (8)

Country Link
EP (1) EP0747051B1 (es)
JP (1) JPH11506771A (es)
AU (1) AU6040296A (es)
BR (1) BR9609053A (es)
CA (1) CA2223175A1 (es)
DE (1) DE69622472T2 (es)
ES (1) ES2180702T3 (es)
WO (1) WO1996040130A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP2314295B1 (en) 2005-07-29 2015-01-28 Resverlogix, Inc Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
CN101970416B (zh) 2008-06-26 2014-05-28 雷斯韦洛吉克斯公司 制备喹唑啉酮衍生物的方法
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
AU2010224523B2 (en) 2009-03-18 2014-05-08 Resverlogix Corp. Novel anti-inflammatory agents
LT2421533T (lt) 2009-04-22 2018-12-27 Resverlogix Corp. Nauji priešuždegiminiai agentai
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
AU698389B2 (en) * 1993-12-21 1998-10-29 Eli Lilly And Company Methods for inhibiting LDL oxidation and atheroclerosis
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin

Also Published As

Publication number Publication date
EP0747051A3 (en) 1997-02-26
BR9609053A (pt) 1999-01-26
AU6040296A (en) 1996-12-30
EP0747051B1 (en) 2002-07-24
CA2223175A1 (en) 1996-12-19
EP0747051A2 (en) 1996-12-11
JPH11506771A (ja) 1999-06-15
DE69622472T2 (de) 2003-02-06
DE69622472D1 (de) 2002-08-29
WO1996040130A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
ES2180702T3 (es) Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
ES2102154T3 (es) Inhibicion de trombina.
FI20011100A (fi) Menetelmä terapeuttisesti käyttökelpoisten trisyklisten bentsatsepiinien valmistamiseksi
ATE196140T1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
ES2175336T3 (es) Derivados de triazol utiles en terapia.
ES2193142T3 (es) Uso de benzotiofenos para el tratamiento de hipercolesterolemia.
EA200801805A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EA199700111A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина
ES2122456T3 (es) Aminoacidos excitadores sinteticos.
UY24935A1 (es) Antagonistas del receptor de vitronectina
ATE25682T1 (de) Indol-3-carboxamid-derivate.
KR910016915A (ko) 과콜레스테롤혈증 치료제
DE69431035D1 (de) 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression
ES2195089T3 (es) Benzotiofenos amorfos, procedimientos de preparacion y uso.
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.
HU913891D0 (en) Method for producing new phenyl-alkyl-amino-alkyl derivatives and medical preparatives containing said compounds
DK0404055T3 (da) Antimetastatisk virksomt stof fra den sydamerikanske igle Haementeria ghilianii
SE9400810D0 (sv) New use of Quinoline-3-carboxamide compounds
ES2195313T3 (es) Derivados de imino-aza-antraciclinona para el tratamiento de la amiloidosis.
RU98123606A (ru) Способ лечения псориаза
ES2052730T3 (es) Mejoras en o relativas a antagonistas de leucotrienos.
DE50211559D1 (en) Hydrophilieadditive
KR940005541A (ko) 치환된 벤조에이트 유도체